These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

499 related articles for article (PubMed ID: 20943082)

  • 1. [Nevirapine related hepatotoxicity: the prevalence and risk factors in a cohort of ART naive Han Chinese with AIDS].
    Gao SC; Gui XE; Deng LP; Zhang YX; Yan YJ; Rong YP; Liang K; Yang RR
    Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):689-93. PubMed ID: 20943082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese.
    Gao S; Gui XE; Deng L; Zhang Y; Liang K; Yang R; Yan Y; Rong Y
    Hepatol Res; 2010 Apr; 40(4):287-94. PubMed ID: 20070390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
    J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
    Colafigli M; Di Giambenedetto S; Bracciale L; Fanti I; Prosperi M; Cauda R; De Luca A
    HIV Med; 2009 Sep; 10(8):461-9. PubMed ID: 19459991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity in patients prescribed efavirenz or nevirapine.
    Brück S; Witte S; Brust J; Schuster D; Mosthaf F; Procaccianti M; Rump JA; Klinker H; Petzold D; Hartmann M
    Eur J Med Res; 2008 Jul; 13(7):343-8. PubMed ID: 18700192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
    Li T; Dai Y; Kuang J; Jiang J; Han Y; Qiu Z; Xie J; Zuo L; Li Y
    PLoS One; 2008; 3(12):e3918. PubMed ID: 19081791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
    Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
    AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
    Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
    BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
    Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E
    BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
    Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
    J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients.
    Gao S; Gui XE; Liang K; Liu Z; Hu J; Dong B
    AIDS Res Hum Retroviruses; 2012 Jun; 28(6):540-3. PubMed ID: 21902584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
    HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
    AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
    Ouyang DW; Shapiro DE; Lu M; Brogly SB; French AL; Leighty RM; Thompson B; Tuomala RE; Hershow RC
    AIDS; 2009 Nov; 23(18):2425-30. PubMed ID: 19617813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.